You are here

Article Text

Article menu
Download PDFPDF
Letter
Topical dorzolamide and metabolic acidosis in a neonate
  1. S Morris1,2,
  2. V Geh1,2,
  3. K K Nischal1,2,
  4. S Sahi3,
  5. M A S Ahmed3
  1. 1Department of Ophthalmology, Great Ormond Street Hospital for Children, London WC1N 3JH, UK
  2. 2Visual Science Unit, Institute of Child Health, London, UK
  3. 3Department of Paediatrics, King George Hospital, Barley Lane, Ilford, IG3 8YB, UK
  1. Correspondence to: Mr Ken K Nischal, Department of Ophthalmology, Great Ormond Street Hospital for Children, London WC1N 3JH, UK; kkn{at}btinternet.com

https://doi.org/10.1136/bjo.87.8.1052

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We describe a neonate with bilateral Peter’s anomaly who became unwell and developed a metabolic acidosis after commencing topical dorzolamide. He was fully investigated to exclude other causes of acidosis, and subsequently improved on discontinuation of topical treatment. To the best of our knowledge, there have been no reports of topical carbonic anhydrase inhibitors causing metabolic acidosis in children or adults.

    A 5 day old boy was referred to a tertiary paediatric ophthalmology unit with bilateral corneal opacities for consideration of penetrating keratoplasty. He had a normal Apgar score at delivery at 35 weeks’ gestation and weight 2.3 kg. In addition, he had had full screening investigations including blood gases, abdominal ultrasound, and DMSA scans because of a prenatal history of intrauterine growth retardation with suspicion of a single kidney.

    Ocular examination revealed total left corneal opacification and a small …

    View Full Text